Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.

Du Q, Wang YJ, Yang S, Zhao YY, Han P

Advances in therapy12 Nov 2014Cited by 19 (Europe PMC)

PMID25388240DOI10.1007/s12325-014-0164-2PepBankPUB-25388240

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomized placebo-controlled trials in type 2 diabetes, liraglutide lowered glycosylated hemoglobin more than placebo.
In plain wordsAcross trials in people with type 2 diabetes, liraglutide lowered average blood sugar control (glycosylated hemoglobin) more than placebo.
Peptide
Liraglutide
Outcome
DecreaseGlycosylated hemoglobin (HbA1c)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
SMD
−0.96
HbA1c, liraglutide vs placebo
Source sentences
Summary
P < 0.0001, SMD = -0.96, 95% CI = [-1.20, -0.73]
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of liraglutide on lowering glycosylated hemoglobin, fasting plasma glucose, reducing weight, lowering blood pressure, and the prevalence of adverse events were significantly different from placebo
Summary · context
We searched randomized controlled trials comparing liraglutide and placebo for the treatment of T2DM in the following databases: MEDLINE; EMBASE; Cochrane Library Central Register of Controlled Trials; and Clinical Trials Gov (through August 2014).
Summary · context
Initially, 103 articles were retrieved through the literature search and 11 studies met the requirements for the meta-analysis.
Report a problemFND-2538824001
02HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomized placebo-controlled trials in type 2 diabetes, liraglutide lowered fasting plasma glucose more than placebo.
In plain wordsAcross trials in people with type 2 diabetes, liraglutide lowered fasting blood glucose more than placebo.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
SMD
−0.72
fasting plasma glucose, liraglutide vs placebo
Source sentences
Summary
P < 0.0001, SMD = -0.72, 95% CI = [-0.99, -0.45]
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of liraglutide on lowering glycosylated hemoglobin, fasting plasma glucose, reducing weight, lowering blood pressure, and the prevalence of adverse events were significantly different from placebo
Summary · context
We searched randomized controlled trials comparing liraglutide and placebo for the treatment of T2DM in the following databases: MEDLINE; EMBASE; Cochrane Library Central Register of Controlled Trials; and Clinical Trials Gov (through August 2014).
Summary · context
Initially, 103 articles were retrieved through the literature search and 11 studies met the requirements for the meta-analysis.
Report a problemFND-2538824002
03HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomized placebo-controlled trials in type 2 diabetes, liraglutide reduced body weight more than placebo.
In plain wordsAcross trials in people with type 2 diabetes, liraglutide reduced body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
SMD
−0.24
body weight, liraglutide vs placebo
Source sentences
Summary
P = 0.004, SMD = -0.24, 95% CI = [-0.40, -0.07]
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of liraglutide on lowering glycosylated hemoglobin, fasting plasma glucose, reducing weight, lowering blood pressure, and the prevalence of adverse events were significantly different from placebo
Summary · context
We searched randomized controlled trials comparing liraglutide and placebo for the treatment of T2DM in the following databases: MEDLINE; EMBASE; Cochrane Library Central Register of Controlled Trials; and Clinical Trials Gov (through August 2014).
Summary · context
Initially, 103 articles were retrieved through the literature search and 11 studies met the requirements for the meta-analysis.
Report a problemFND-2538824003
04HumanSystematic reviewEfficacy outcome
In a meta-analysis of randomized placebo-controlled trials in type 2 diabetes, liraglutide lowered systolic blood pressure more than placebo.
In plain wordsAcross trials in people with type 2 diabetes, liraglutide lowered systolic blood pressure more than placebo.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
SMD
−0.15
blood pressure, liraglutide vs placebo
Source sentences
Summary
P = 0.021, SMD = -0.15, 95% CI = [-0.27, -0.02]
3 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide had greater hypoglycemic, weight-reducing and systolic blood pressure-lowering effects than placebo.
Summary · context
We searched randomized controlled trials comparing liraglutide and placebo for the treatment of T2DM in the following databases: MEDLINE; EMBASE; Cochrane Library Central Register of Controlled Trials; and Clinical Trials Gov (through August 2014).
Summary · context
Initially, 103 articles were retrieved through the literature search and 11 studies met the requirements for the meta-analysis.
Report a problemFND-2538824004
05HumanSystematic reviewSafety outcome
In a meta-analysis of randomized placebo-controlled trials in type 2 diabetes, adverse events were more frequent with liraglutide than with placebo.
In plain wordsAcross trials in people with type 2 diabetes, side effects were more common with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreasePrevalence of adverse events
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
and P = 0.007, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
However, there were more adverse events in the treatment with liraglutide.
Summary · context
We searched randomized controlled trials comparing liraglutide and placebo for the treatment of T2DM in the following databases: MEDLINE; EMBASE; Cochrane Library Central Register of Controlled Trials; and Clinical Trials Gov (through August 2014).
Summary · context
Initially, 103 articles were retrieved through the literature search and 11 studies met the requirements for the meta-analysis.
Report a problemFND-2538824005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 3NCT06894784

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

McGill University Health Centre/Research Institute of the McGill University Health Centren = 36est. Apr 2025 to est. Jan 2027

Diabetes Type 1

Trial page ClinicalTrials.govUpdated 30 Mar 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.